Biosimilars Conference

Menu Back to Biosimilars-Conference

Overview

Conference | September 20-21

At the DIA Biosimilars Conference 2022, manufacturers, regulators, payers, prescribers, and patients will convene to discuss factors that influence biosimilar development, and access, and share perspectives on what success and progress looks like to provide cost-saving options for providers and patients in need.

Attendees will apply practical solutions and forward-thinking learnings from around the world, to help build strategies for growth of the biosimilar's market.

Testimonial:

“At this year’s conference, I will be addressing why confidence in using biosimilar medicines is at its highest today. In an exchange with colleagues from across the biosimilar landscape including regulators & patient representatives we will look at what remains to be done collectively so that these medicines can reach all the patients that need them in a timely fashion.” Julie Maréchal-Jamil, Director, Biosimilars Policy & Science; Medicines for Europe, Belgium

Event Goals and Offerings
- Increase understanding of access to safe, effective, and cost-effective biological treatment options
- Collaborate with professionals in science, regulation, R&D, and more, to address barriers in biosimilar development
- Eliminate misinformation that delays policies to increase patient access
- Streamline global and regional goals with all stakeholder perspectives
Why You Can’t Miss It
- Increase potential of and access to the biosimilar's market
- Meet and network with professionals involved in ongoing regulatory, manufacturing, pricing, and educational challenges
- Discuss influencing factors of biosimilar development by including stakeholders embedded in this space
- Apply the newest thinking and global learnings for strategic growth in biosimilar product development
- Incorporate viewpoints of manufacturers, regulators, payers, prescribers, and patients altogether
Learning Objectives

At the conclusion of this activity, participants should be able to:
- Describe key biosimilar-related regulatory developments and initiatives in participating jurisdictions
- Describe the future market for biosimilar development
- Prepare and adjust product development plans in light of the evolving regulatory landscape
- Assess the impact of biosimilars in conquering disparities in access to medicines
- Identify the differences in patient access to biologics/biosimilars by region
- Describe the policy solutions needed to improve access to biosimilars
- Evaluate and understand the power of payers’ formulary positioning in encouraging biosimilar use
- Devise plans for implementation while leveraging clinical experience obtained in markets similar to the US
- Identify the tendencies and different perspectives on the evolution of data requirements for licensing of biosimilars from regulators, HCPs, industry, and patient association representatives
Meeting Designed For
- Biosimilar/Biologic Pharmaceutical Research
- Biomedical Product Development & Manufacturing
- Regulatory Affairs
- (Non)Clinical Research
- Business & Data Management
- Business Development
- Marketing & Commercialization for biosimilars
- Medical Communications/MSLs
- Patient Advocacy/Patient Support Programs
- Health & medical care across therapeutic disciplines
- Health Education
- Provision of prescription products
- Development & management of prescription product formularies
- Development & management of prescription benefit plans
- Quality management

Program Committee

Leah Christl, PhD • Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
Amgen, United States
Tiffany Fletcher, MA • Head of Global Access Policy
Viatris, United States
Denis Arsenault, MA • Manager, Policy Development
Health Canada, Canada
Mauricio Ede, MD, PhD • Chief Medical & Scientific Officer
Sandoz Canada Inc., Canada
Stanton Mehr • Director of Content
Biosimilars Review and Report, United States
Juliana Marguerite Reed, MS • Executive Director
The Biosimilars Forum, United States
Stacey Ricci, DrSc • Director, Scientific Review Staff, OTBB, OND, CDER
FDA, United States
Cecil J. Nick, MS • FTOPRA, Vice President (Technical)
Parexel Consulting, United Kingdom